hpv疫苗 相關
廣告Offer the best service for Parvovirus B19/Canine Parvovirus vaccine development. Provide global solution for worldwide customers in the field of viral vaccine development.
搜尋結果
A conjugate vaccine is a type of subunit vaccine which combines a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen. Vaccines are used to prevent diseases by invoking an immune response to an antigen, part of a bacterium or virus that the immune system recognizes. [2]
Hepatitis B vaccine is a vaccine that prevents hepatitis B.[13] The first dose is recommended within 24 hours of birth with either two or three more doses given after that.[13] This includes those with poor immune function such as from HIV/AIDS and those born premature.[13] It is also recommended that health-care workers be vaccinated.[14] In ...
A poster advertising trials of the RTS,S vaccine RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine.It is one of two malaria vaccines approved (the other is R21/Matrix-M).As of April 2022, the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production ...
The Vi capsular polysaccharide vaccine (or ViCPS) is a typhoid vaccine recommended by the World Health Organization for the prevention of typhoid (another is Ty21a ). The vaccine was first licensed in the US in 1994 and is made from the purified Vi capsular polysaccharide from the Ty2 Salmonella Typhi strain; it is a subunit vaccine .
Tick-borne encephalitis vaccine is a vaccine used to prevent tick-borne encephalitis (TBE).[4] The disease is most common in Central and Eastern Europe, and Northern Asia.[4] More than 87% of people who receive the vaccine develop immunity.[5] It is not useful following the bite of an infected tick.[4] It is given by injection into a muscle.[4 ...
MVA85A. MVA85A (modified vaccinia Ankara 85A) is a vaccine against tuberculosis developed by researchers led by Professor Helen McShane at Oxford University. [1] It is a viral vector vaccine and consists of an MVA virus engineered to express the 85A antigen once it infects a host cell. 85A is a cell-wall protein of the tuberculosis bacillus .
CoronaVac, also known as the Sinovac COVID-19 vaccine, is a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was phase III clinically trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine ...
